Please use this identifier to cite or link to this item:
Title: Defining the next generation of Plasmodium vivax diagnostic tests for control and elimination: Target product profiles
Author: Ding, Xavier C.
Ade, Maria Paz
Baird, J. Kevin
Cheng, Qin
Cunningham, Jane
Dhorda, Mehul
Drakeley, Chris
Felger, Ingrid
Gamboa, Dionicia
Harbers, Matthias
Herrera, Sócrates
Lucchi, Naomi
Mayor Aparicio, Alfredo Gabriel
Mueller, Ivo
Sattabongkot, Jetsumon
Ratsimbason, Arsène
Richards, Jack
Tanner, Marcel
Gonzalez, Iveth J.
Keywords: Plasmodium vivax
Malalties parasitàries
Plasmodium vivax
Parasitic diseases
Issue Date: 3-Apr-2017
Publisher: Public Library of Science (PLoS)
Abstract: The global prevalence of malaria has decreased over the past fifteen years, but similar gains have not been realized against Plasmodium vivax because this species is less responsive to conventional malaria control interventions aimed principally at P. falciparum. Approximately half of all malaria cases outside of Africa are caused by P. vivax. This species places dormant forms in human liver that cause repeated clinical attacks without involving another mosquito bite. The diagnosis of acute patent P. vivax malaria relies primarily on light microscopy. Specific rapid diagnostic tests exist but typically perform relatively poorly compared to those for P. falciparum. Better diagnostic tests are needed for P. vivax. To guide their development, FIND, in collaboration with P. vivax experts, identified the specific diagnostic needs associated with this species and defined a series of three distinct target product profiles, each aimed at a particular diagnostic application: (i) point-of-care of acutely ill patients for clinical care purposes; (ii) point-of-care asymptomatic and otherwise sub-patent residents for public health purposes, e.g., mass screen and treat campaigns; and (iii) ultra-sensitive not point-of-care diagnosis for epidemiological research/surveillance purposes. This report presents and discusses the rationale for these P. vivax-specific diagnostic target product profiles. These contribute to the rational development of fit-for-purpose diagnostic tests suitable for the clinical management, control and elimination of P. vivax malaria.
Note: Reproducció del document publicat a:
It is part of: PLoS Neglected Tropical Diseases, 2017, vol. 11, num. 4, p. e0005516
Related resource:
ISSN: 1935-2727
Appears in Collections:Articles publicats en revistes (ISGlobal)

Files in This Item:
File Description SizeFormat 
ding2017_2491.pdf949.39 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons